In addition, BMMC from MM patients (N = 5) treated with anti-LAG3 had significantly higher (*p < 0.05) T-cell proliferation than with the other clinical grade immune modulators, upon stimulation with the mixture of ten different MM cell lines, either as irradiated whole cells or tumor lysates. This evidence concerns the gene LAG3 and neoplasm.